{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-peptic-ulcer/prescribing-information/tetracycline/","result":{"pageContext":{"chapter":{"id":"b8602cfd-a10c-5663-b691-a8ca11b0ed81","slug":"tetracycline","fullItemName":"Tetracycline","depth":2,"htmlHeader":"<!-- begin field eaa6f0f6-95ee-41bf-a678-a76d00f43e0b --><h2>Tetracycline</h2><!-- end field eaa6f0f6-95ee-41bf-a678-a76d00f43e0b -->","summary":"","htmlStringContent":"<!-- begin item f6f4b371-4683-4985-b10a-a76d00f43c38 --><!-- end item f6f4b371-4683-4985-b10a-a76d00f43c38 -->","topic":{"id":"4d7c8c68-3a8f-5975-99a6-50cb32ce9c94","topicId":"3ad099a3-2ca3-4327-9bda-99105ccbd251","topicName":"Dyspepsia - proven peptic ulcer","slug":"dyspepsia-proven-peptic-ulcer","lastRevised":"Last revised in October 2019","chapters":[{"id":"b126bb0b-6cc6-5fb5-a165-08590aab0070","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7966dab4-9ee2-5d7d-8253-890904345546","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"863af072-467d-558f-a5a4-938251ca4b70","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c6e3fda6-22f9-51b3-94d8-fc248cda56bd","slug":"changes","fullItemName":"Changes"},{"id":"d90954aa-bfcf-53f9-bf54-94b6f90fc75f","slug":"update","fullItemName":"Update"}]},{"id":"b8e40cd5-8e95-5335-9d56-292936d0d7a7","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b8925c36-3dae-5ec7-8277-83b343cdc753","slug":"goals","fullItemName":"Goals"},{"id":"99d05347-f238-52f8-a91d-6367fc2a4c84","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2658a735-068a-5b5a-b9de-83da5c0d4c04","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6e095fbb-fc3e-5b4e-aec2-bf80df353e31","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90cb6b5a-e54b-565d-809f-76ac723d4bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a584a99-78fc-5b5b-8ae6-b14250c00325","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"df3e0e6a-10b7-5ced-9c05-dff646629460","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f35e4de1-c942-50cb-aef3-91b3c4def480","slug":"definition","fullItemName":"Definition"},{"id":"a8810be9-e85c-535f-9ccd-50aee78e9c8b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"da86cd41-e515-572c-aa44-9330eba9ac28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f5dd15bb-7399-5245-8f59-87a9790a59a7","slug":"complications","fullItemName":"Complications"},{"id":"126a2719-f8ba-5188-ac87-dcecfe57ea0e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"6278e7c4-7eeb-5045-b77c-00b84f08b040","fullItemName":"Management","slug":"management","subChapters":[{"id":"be22af5a-19ce-5791-8415-1297662b5e10","slug":"management-proven-peptic-ulcer","fullItemName":"Scenario: Management - proven peptic ulcer"}]},{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"967aa284-35b6-5f7c-838f-5dbbda36ac93","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"e2e731b3-6cb9-5268-b8c9-9839738dcf7f","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"59f31401-2de6-5276-9ffc-800e8e519e95","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9eb0d371-d052-5fd9-ba58-45fcf40cbbfe","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"d2ff9ee7-1022-5cb2-aa78-f65bf08be543","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"b8602cfd-a10c-5663-b691-a8ca11b0ed81","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"f17ce37f-6d62-5780-b8d9-9426dcd13e56","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"9eb2f48d-68e2-51ca-acee-8ae753fa0e83","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"5d80e758-2b4f-50bd-957d-658701dadd77","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5d902b88-104e-572b-9dcd-f4035f35a4c5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b954b837-c685-5f3f-b569-e2a1cc897ef4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1ddadd9-ccea-5965-9c2f-6e2848db1f33","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"49079197-90f7-5a71-9f31-cd48ba3d7e9b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"201aafd4-5cd3-5f8d-9ac0-364e8cd95e53","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ea362840-d561-5944-8292-1f1c7a1feef4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c1e4fdd8-fd8a-5191-aaf4-fb43c1ed5a7f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ab1a41e7-bcd1-5497-be85-4ddd27856ea1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0fa8d314-8f9a-4f2a-9ed0-a76d00f47b52 --><h3>Contraindications and cautions</h3><!-- end field 0fa8d314-8f9a-4f2a-9ed0-a76d00f47b52 -->","summary":"","htmlStringContent":"<!-- begin item d0bdf331-a5e1-458d-9776-a76d00f4793a --><!-- begin field eafc7bef-b330-4eb3-aa71-a76d00f47b52 --><ul><li><strong>Do not prescribe tetracycline to people with:</strong><ul><li>Renal impairment — tetracyclines are excreted renally and may exacerbate renal failure.</li></ul></li><li><strong>Prescribe tetracycline with caution to people with:</strong><ul><li>Hepatic impairment and those receiving potentially hepatotoxic drugs, such as carbamazepine, isoniazid, and methotrexate.</li><li>Myasthenia gravis — tetracyclines may increase muscle weakness symptoms.</li><li>Systemic lupus erythematosus (SLE) — tetracyclines may exacerbate the condition.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</p><!-- end field eafc7bef-b330-4eb3-aa71-a76d00f47b52 --><!-- end item d0bdf331-a5e1-458d-9776-a76d00f4793a -->","subChapters":[]},{"id":"88b41f28-62c9-54e0-ac0c-5a351c4461d9","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9f8c3639-2dea-47c0-bbbf-a76d00f495dc --><h3>Adverse effects</h3><!-- end field 9f8c3639-2dea-47c0-bbbf-a76d00f495dc -->","summary":"","htmlStringContent":"<!-- begin item 3755b07d-8c02-488d-8f5d-a76d00f49400 --><!-- begin field 582ee6e6-a6da-45dc-9c74-a76d00f495dc --><ul><li><strong>Common adverse effects of tetracycline include:</strong><ul><li>Gastrointestinal disturbances such as nausea, vomiting, and diarrhoea.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with tetracycline. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li>Dysphagia and oesophageal irritation.</li></ul></li><li><strong>Other rare adverse effects of tetracyclines include:</strong><ul><li>Severe headache and/or visual disturbance — may be an early symptom of benign intracranial hypertension. Stop treatment and seek immediate medical advice if this is suspected.</li><li>Severe oesophagitis.</li><li>Vulvovaginal candidiasis.</li><li>Photosensitivity.</li><li>Hepatotoxicity, pancreatitis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</p><!-- end field 582ee6e6-a6da-45dc-9c74-a76d00f495dc --><!-- end item 3755b07d-8c02-488d-8f5d-a76d00f49400 -->","subChapters":[]},{"id":"4987e464-f88e-5224-86ec-ef1f4eb21dae","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 02e46eed-ce7d-4a48-8005-a76d00f4a49f --><h3>Drug interactions</h3><!-- end field 02e46eed-ce7d-4a48-8005-a76d00f4a49f -->","summary":"","htmlStringContent":"<!-- begin item 9d86145c-d963-41e0-8e73-a76d00f4a2db --><!-- begin field e235dd71-3456-47e8-95a2-a76d00f4a49f --><p><strong>Possible drug interactions with tetracycline include:</strong></p><ul><li><strong>Antacids (containing aluminium, bismuth, calcium, or magnesium) and other medications containing iron or zinc </strong>— these reduce the absorption of tetracyclines if taken concurrently.<ul><li>Avoid taking antacids and other medications containing iron or zinc, 2 hours before or after taking tetracyclines.</li></ul></li><li><strong>Anticoagulants </strong>— the concurrent use of warfarin with tetracyclines can increase the anticoagulant effect of coumarins.<ul><li>Monitor the person's international normalized ratio (INR) regularly and within 3 days of starting the tetracycline. Adjust the warfarin dose accordingly.</li></ul></li><li><strong>Retinoids</strong> — there is a possible increased risk of benign intracranial pressure if tetracyclines are used concurrently with retinoids.<ul><li>Avoid the concurrent use of tetracyclines and retinoids.</li></ul></li><li><strong>Milk </strong>— the absorption of most tetracyclines is reduced by the calcium found in milk and other dairy products.</li><li><strong>Carbamazepine </strong>— doxycycline levels are reduced significantly in people taking long-term carbamazepine.</li><li><strong>Penicillins </strong>— tetracyclines possibly antagonize the effects of penicillins.</li><li><strong>Sulfonylureas </strong>— tetracyclines possibly enhance the hypoglycaemic effects of sulfonylureas.</li><li><strong>Tripotassium dicitratobismuthate </strong>— absorption of tetracyclines is reduced.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">BNF 72, 2016</a>]</p><!-- end field e235dd71-3456-47e8-95a2-a76d00f4a49f --><!-- end item 9d86145c-d963-41e0-8e73-a76d00f4a2db -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}